Literature DB >> 11839763

Hypobetalipoproteinemic mice with a targeted apolipoprotein (Apo) B-27.6-specifying mutation: in vivo evidence for an important role of amino acids 1254-1744 of ApoB in lipid transport and metabolism of the apoB-containing lipoprotein.

Zhouji Chen1, Robin L Fitzgerald, Gustav Schonfeld.   

Abstract

Carboxyl-terminal deletion of apoB-100 may impair its triglyceride (TG)-transporting capability and alter its catabolism. Here, we compare our newly generated apoB gene (Apob)-targeted apoB-27.6-bearing mice to our previously reported apoB-38.9 mice to understand further the relationship between the size of a truncated apoB variant and its function/metabolism in vivo. The apoB-27.6-specifying mutation produces a premature stop codon six amino acids (aa) downstream of the last codon of mouse Apob exon 24 (corresponding to aa 1254 of human apoB-100). ApoB-27.6 transcripts were 3- and 5-fold more abundant than apoB wild type and apoB-38.9 transcripts in the liver. Likewise, hepatic secretion rates of apoB-27.6 were 7-fold higher than those of apoB-48 and apoB-38.9. In contrast, apoB-27.6 heterozygotes (Apob(27.6/+)) had lower hepatic TG secretion rates and higher liver TG contents than both apoB-38.9 heterozygotes (Apob(38.9/+)) and apoB wild type mice (Apob(+/+)). ApoB-27.6 was secreted by Apob(27.6/+) hepatocytes as dense high density lipoprotein particles. Moreover, despite its high secretion rates, apoB-27.6 was barely detectable in plasma. Disruption of apoE gene in Apob(38.9/+) and Apob(27.6/+) dramatically increased plasma levels of apoB-38.9 as well as apoB-48 but caused no change in plasma apoB-27.6 concentrations. Finally, the birth rate of apoB-27.6 homozygotes (Apob(27.6/27.6)) from intercrosses of Apob(27.6/+) was 7-fold lower than that of Apob(38.9/38.9) from Apob(38.9/+) intercrosses (1.8% versus 12%). Crossbreeding of Apob(27.6/27.6) and Apob(38.9/38.9) produced viable Apob(27.6/38.9) offspring, but Apob(27.6/27.6) intercrosses produced no offspring. Together, these results demonstrate in vivo that the apoB-27.6-apoB-38.9 peptide segment (aa 1254-1744) plays a critical role, not only in supporting hepatic TG-secretion and in modulating catabolism of apoB-containing lipoproteins, but also in normal mouse embryonic development.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11839763     DOI: 10.1074/jbc.M200617200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

Review 1.  Endoplasmic reticulum quality control in lipoprotein metabolism.

Authors:  Cari M Koerner; Benjamin S Roberts; Saskia B Neher
Journal:  Mol Cell Endocrinol       Date:  2019-08-20       Impact factor: 4.102

2.  Loss of apolipoprotein E exacerbates the neonatal lethality of the Smith-Lemli-Opitz syndrome mouse.

Authors:  Curzio Solcà; Bhaswati Pandit; Hongwei Yu; G Stephen Tint; Shailendra B Patel
Journal:  Mol Genet Metab       Date:  2007-01-02       Impact factor: 4.797

3.  Peroxisome proliferator-activated receptor-gamma coactivator-1alpha (PGC-1alpha) stimulates VLDL assembly through activation of cell death-inducing DFFA-like effector B (CideB).

Authors:  Zhouji Chen; Jin Y Norris; Brian N Finck
Journal:  J Biol Chem       Date:  2010-06-15       Impact factor: 5.157

4.  Alterations in hepatic metabolism in fld mice reveal a role for lipin 1 in regulating VLDL-triacylglyceride secretion.

Authors:  Zhouji Chen; Matthew C Gropler; Jin Norris; John C Lawrence; Thurl E Harris; Brian N Finck
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-07-31       Impact factor: 8.311

5.  Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion.

Authors:  Meenakshi Sundaram; Zemin Yao
Journal:  Nutr Metab (Lond)       Date:  2010-04-27       Impact factor: 4.169

6.  Nonsynonymous mutations within APOB in human familial hypobetalipoproteinemia: evidence for feedback inhibition of lipogenesis and postendoplasmic reticulum degradation of apolipoprotein B.

Authors:  Shumei Zhong; Antonia Lucia Magnolo; Meenakshi Sundaram; Hu Zhou; Erik F Yao; Enza Di Leo; Paola Loria; Shuai Wang; Michelle Bamji-Mirza; Lisheng Wang; C Jamie McKnight; Daniel Figeys; Yuwei Wang; Patrizia Tarugi; Zemin Yao
Journal:  J Biol Chem       Date:  2009-12-23       Impact factor: 5.157

7.  Interrogation of selected genes influencing serum LDL-Cholesterol levels in patients with well characterized NAFLD.

Authors:  Eduardo Vilar-Gomez; Samer Gawrieh; Tiebing Liang; Adam D McIntyre; Robert A Hegele; Naga Chalasani
Journal:  J Clin Lipidol       Date:  2020-12-27       Impact factor: 4.766

8.  Lipoprotein metabolism in nonalcoholic fatty liver disease.

Authors:  Zhenghui Gordon Jiang; Simon C Robson; Zemin Yao
Journal:  J Biomed Res       Date:  2012-12-01

9.  Apolipoprotein B100 quality control and the regulation of hepatic very low density lipoprotein secretion.

Authors:  Eric Fisher; Elizabeth Lake; Roger S McLeod
Journal:  J Biomed Res       Date:  2014-03-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.